Literature DB >> 17989944

[Scoring systems for clinical staging of peritoneal carcinomatosis. A critical analysis].

J Jähne1, S Kübler.   

Abstract

For peritoneal carcinomatosis, several different classification and scoring systems for clinical staging have been proposed and used by the different centers worldwide engaged in treating this clinical entity. Of highest clinical relevance are the classifications assessing tumor distribution and size and those describing the degree of surgical cytoreduction. Allocation of patients to different stages is based on clinical intraoperative evaluation and therefore is subjective and observer-dependent. The various classification systems are presented and discussed regarding applicability, exactness, and their value as either selection criterion or prognostic instrument.

Entities:  

Mesh:

Year:  2007        PMID: 17989944     DOI: 10.1007/s00104-007-1426-1

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  40 in total

1.  Treatment of peritoneal carcinomatosis with intent to cure.

Authors:  F Cavaliere; P Perri; F Di Filippo; D Giannarelli; C Botti; M Cosimelli; M Tedesco; F Principi; L Laurenzi; R Cavaliere
Journal:  J Surg Oncol       Date:  2000-05       Impact factor: 3.454

2.  Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy.

Authors:  P H Sugarbaker; D Chang
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

3.  Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique.

Authors:  Shigeki Kusamura; Rami Younan; Dario Baratti; Pasqualina Costanzo; Myriam Favaro; Cecilia Gavazzi; Marcello Deraco
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

4.  Synchronous extraperitoneal and intraperitoneal dissemination of appendix cancer.

Authors:  C Pablo Carmignani; P H Sugarbaker
Journal:  Eur J Surg Oncol       Date:  2004-10       Impact factor: 4.424

5.  Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome.

Authors:  Vic J Verwaal; Henk Boot; Berthe M P Aleman; Harm van Tinteren; Frans A N Zoetmulder
Journal:  Ann Surg Oncol       Date:  2004-03-15       Impact factor: 5.344

6.  Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features.

Authors:  A G Portilla; P H Sugarbaker; D Chang
Journal:  World J Surg       Date:  1999-01       Impact factor: 3.352

7.  Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.

Authors:  A-A K Tentes; G Tripsiannis; S K Markakidis; C N Karanikiotis; G Tzegas; G Georgiadis; K Avgidou
Journal:  Eur J Surg Oncol       Date:  2003-02       Impact factor: 4.424

8.  Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.

Authors:  Perry Shen; Edward A Levine; Jason Hall; Doug Case; Greg Russell; Ronald Fleming; Richard McQuellon; Kim R Geisinger; Brian W Loggie
Journal:  Arch Surg       Date:  2003-01

9.  Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.

Authors:  D Elias; T Matsuhisa; L Sideris; G Liberale; L Drouard-Troalen; B Raynard; M Pocard; J M Puizillou; V Billard; P Bourget; M Ducreux
Journal:  Ann Oncol       Date:  2004-10       Impact factor: 32.976

10.  Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Rhonda L Harmon; Paul H Sugarbaker
Journal:  Int Semin Surg Oncol       Date:  2005-02-08
View more
  1 in total

1.  [Advanced gastric cancer. Are there still indications for palliative surgical interventions?].

Authors:  I Gastinger; U Ebeling; L Meyer; F Meyer; U Schmidt; S Wolff; H Ptok; H Lippert
Journal:  Chirurg       Date:  2012-05       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.